Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented): A method of inducing, in a human, serum antibodies which protect against infection with S. *typhi*, comprising administering to said human, a composition comprising a molecular conjugate of the S. *typhi* Vi polysaccharide comprising an N-acetyl group and covalently bound through a carboxylic acid dihydrazide linker to *Pseudomonas aeruginosa* recombinant exoprotein A in a pharmaceutically acceptable carrier.

Claim 2 (canceled)

Claim 3 (previously presented): The method of claim 1 wherein said conjugate molecule is administered at a dose of about 3 micrograms to about 50 micrograms of S. *typhi* Vi polysaccharide.

Claim 4 (original): The method of claim 3 wherein said conjugate molecule is administered at a dose of about 25 micrograms of Vi polysaccharide.

Claim 5 (previously amended): The method of claim 1 wherein the antibodies protect the human against infection by S. *typhi*.

Claims 6-11 (canceled)

Claim 12 (currently amended): A method for vaccinating a human against S. *typhi* infection, comprising administering to the human an immunizing amount of a composition comprising a molecular conjugate of S. *typhi* Vi polysaccharide comprising an N-acetyl group and covalently bound through a carboxylic dihydrazide linker of *Pseudomonas aeruginosa* recombinant exoprotein A in a pharmaceutically acceptable carrier[[,]].

Claim 13 (canceled)

Claim 14 (previously presented): A vaccine composition comprising an immunologically effective amount of a molecular conjugate of S. *typhi* Vi polysaccharide comprising an N-acetyl group and covalently bound through a carboxylic acid dihydrazide linker to *Pseudomonas aeruginosa* recombinant exoprotein A, in a pharmaceutically acceptable carrier.

Claim 15 (canceled)

Claim 16 (original): The method of claim 5 wherein the human is a 2 to 3 year old.

Claim 17 (original): The method of claim 5 wherein the human is a 4 to 5 year old.

Claim 18 (original): The method of claim 5 wherein the human is a 5 to 17 year old.

Claim 19 (original): The method of claim 5 wherein the human is an adult.

Claim 20 (original): The method of claim 12 wherein the human is a 2 to 3 year old.

Claim 21 (original): The method of claim 12 wherein the human is a 4 to 5 year old.

Claim 22 (original): The method of claim 12 wherein the human is a 5 to 14 year old.

Claim 23 (original): The method of claim 12 wherein the human is an adult.

Claim 24 (previously presented): The method of claim 1 wherein said Vi polysaccharide is covalently bound to the rEPA by means of an adipic acid dihydrazide linker.

Claim 25 (previously presented): The method of claim 12 wherein the S. *typhi* Vi polysaccharide is covalently bound to the *Pseudomonas aeruginosa* recombinant exoprotein A by means of an adipic acid dihydrazide linker.

Claim 26 (previously presented): The vaccine composition of claim 14 wherein the S. *typhi* Vi polysaccharide is covalently bound to the *Pseudomonas aeruginosa* recombinant exoprotein A by means of an adipic acid dihydrazide linker.

Claim 27 (new): The vaccine composition of claim 14, wherein the vaccine composition is a human vaccine composition.

Claim 28 (new): The vaccine composition of claim 26, wherein the vaccine composition is a human vaccine composition.